HIV-1 Drug Resistance Assay Test - Book at an Affordable Cost

To discover if an HIV patient has a mutant form of the virus that does not answer to antiretroviral therapy, drug resistance experimenting is utilized (ART).

If a patient with HIV develops drug resistance and keeps taking the same treatment, HIV might replicate more quickly since the medication is unable to stop it from doing so. Selective pressure describes the situation where the new, mutant form is preferred. The resilient HIV strain may eventually take over as the predominant form of HIV in the body if it replicates itself sufficiently. When this happens, the medicine mislay its usefulness, and the patient develops antagonism to it.

Resistance Assays Are Used to Determine the First Therapy

It is generally known that the spread of drug-resistant HIV strains is linked to a poor virologic response to the first ART. The incidence of drug resistance among HIV-positive individuals who participate in high-risk behaviors within a given community is correlated with the likelihood of contracting a virus that is resistant to treatment.

The population under study, the location, and the ARV class that is accessible there all influence the occurrence of resistance and mutations by ARV drug class. The problem of pre-existing HIV medication resistance before the start of ART is acknowledged by both high-income and low-income nations. In high-income nations, the preponderance of transferred drug antagonism (TDR) varies by country and varies from 9% to 14%.

Pre-treatment drug resistance, which the World Health Organization defines as those who were exposed to ARVs before beginning first-line therapy (for example, for PrEP or the prevention of perinatal transmission), exceeds 10% in several nations. 20 NNRTI resistance and NRTI resistance are often the most prevalent mutation class types found in TDR surveys, followed by PI- and INSTI-resistant mutations, respectively.

Data Interpretation

This test indicates whether HIV-1 will be resistant to integrase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors. Next Generation Sequencing is used to sequence the viral genome's protease, integrase, and reverse transcriptase genes. With the Stanford HIVDB database, drug resistance is allocated.

Together with other laboratory markers and the clinical presentation, this test should be used. The way a patient responds to treatment depends on several variables, including patient adherence, the prevalence of resistant viruses, dosage, and drug pharmacology problems.

The Cost of HIV-1 Drug Resistance Assay Test

The average price for HIV-1 Drug Resistance Assay test is seen to differ from one center to another. The price range is said to be between  INR 9000 to INR 57000 in Delhi, India.